Silexion Therapeutics Q1 2025 net loss $1.7M; cash $6.2M; SIL204 shows ~70-80% tumor reduction

Silexion Therapeutics Corp

2025-Q1 EPS reported $0.26

Net loss $1.7M in Q1 2025 vs $1.4M in Q1 2024; total operating expenses $1.7M (R&D $0.6M, G&A $1.1M).
Cash and cash equivalents $6.2M as of Mar 31, 2025, up from $1.2M in Dec 31, 2024, after ~$9.2M gross raised.
SIL204 orthotopic data: ~70% tumor cell reduction in AsPC-1 (G12D) and ~80% in BxPC-3 by day 28; reduced metastases.
Expanded dual-route (systemic + intratumoral) development strategy for SIL204; clinical trials targeted for H1 2026.
Post-quarter strategic collaboration with Catalent for formulation and clinical manufacturing of SIL204.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.